Evidence map›Paper›PMID 41624374›Full record

ArticleBlood red cells & iron2025

Disease-modifying effects of iron deficiency in mouse models of chronic renal failure.

Moya Zhang, Amber Lundin, Grace Jung, Joseph D Olivera, Veena Sangkhae, Shilpa Sharma, Tomas Ganz, Elizabeta Nemeth, Mark R Hanudel, Brian Czaya

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood red cells & iron, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Molecular and therapeutic frontiers in anemia therapy.The Journal of clinical investigation · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Moya ZhangCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Amber LundinCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.ORCID 0009-0000-4560-587X
Grace JungCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Joseph D OliveraCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Veena SangkhaeCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.ORCID 0000-0001-7397-0815
Shilpa SharmaCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Tomas GanzCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.ORCID 0000-0002-2830-5469
Elizabeta NemethCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.ORCID 0000-0002-3477-2397
Mark R HanudelCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Brian CzayaCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.ORCID 0000-0002-7888-2432

Funding

UCLA Pulmonary and Critical Care Medicine Training ProgramT32HL072752 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JOHN A BELPERIO, TOMAS GANZ · 2003 to 2026
$8.3M
MECHANISM OF ACTION OF ERYTHROFERRONE AND PATHOLOGICAL IMPLICATIONSR01DK126680 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GANZ, TOMAS · 2020 to 2024
$2.6M
Iron deficiency worsens inflammatory tissue injury: mechanisms and outcomesR01DK136691 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2024 to 2026
$1.7M
Iron and Pregnancy: Regulatory Mechanisms and Adverse OutcomesK01DK127004 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SANGKHAE, VEENA · 2021 to 2025
$761k
FGF23 contributes to anemia in Chronic Kidney Disease by elevating hepcidin productionF31DK117550 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CZAYA, BRIAN · 2018 to 2020
$102k
CSRD VA IK2 CX002195NHLBI NIH HHS T32 HL072752NIDDK NIH HHS F31 DK117550NIDDK NIH HHS K01 DK127004NIDDK NIH HHS R01 DK126680NIDDK NIH HHS R01 DK136691
6 · The paper itself

Abstract

Chronic kidney disease (CKD) affects global health, contributing to 1 in 60 fatalities worldwide. Iron deficiency (ID), a common complication of CKD, is a major cause of years lived with disability. The combination of CKD and ID presents a particularly challenging health burden, as ID can exacerbate CKD-related complications and negatively affect patient outcomes. Despite the high prevalence of ID and anemia in patients with CKD, whether and how ID alters CKD-associated complications, such as systemic inflammation, organ fibrosis, vascular calcification, and cardiomyopathy, remains insufficiently understood. Using 2 distinct mouse models of CKD, adenine-induced nephropathy and Alport syndrome (

Identifiers

PMID41624374
PMCPMC12854105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.